Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency | Zendy

Kazuo Ota | Zendy; Tadao Akizawa | Zendy; Yoshihei Hirasawa | Zendy; Tetsuzo Agishi | Zendy; Noriaki Matsui | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency

Author(s) -

Kazuo Ota,

Tadao Akizawa,

Yoshihei Hirasawa,

Tetsuzo Agishi,

Noriaki Matsui

Publication year - 2003

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfg320

Subject(s) - argatroban , medicine , antithrombin , anticoagulant , heparin , hemodialysis , adverse effect , direct thrombin inhibitor , anesthesia , surgery , thrombin , warfarin , dabigatran , atrial fibrillation , platelet

In congenital or acquired antithrombin III-deficient patients undergoing haemodialysis, coagulation or residual blood in the blood circuit and dialyser is commonly observed under anticoagulation with heparin. Argatroban, a synthetic thrombin antagonist, directly inhibits thrombin activity in a manner that is different from that of heparin, thereby displaying an anticoagulating effect without the activation of antithrombin III. For this reason, the anticoagulating effect of argatroban in haemodialysis patients with antithrombin III deficiency was investigated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research